RayBalance
Follow-On / Biosimilar Differentiation
Create administration-performance differentiation for follow-on and biosimilar programs without changing the drug product.
Platform Focus
The Administration Site Matters
A proprietary, non-reformulation platform focused on the SC administration site.
SC delivery performance can be influenced not only by the molecule, formulation, container closure, and device, but also by the local tissue environment where the injection depot forms. RayBalance's proprietary, non-reformulation platform treats the administration site as an addressable delivery-performance variable, while preserving the partner's drug product.
- Preserves the partner drug product
- Focuses on the SC administration environment
- Supports partner-specific evaluation and evidence planning
Illustrative schematic. Technical details are disclosed only under appropriate confidentiality protections.
The Challenge
Why SC Absorption Variability Matters
The same SC dose can produce different exposure profiles.
SC absorption and systemic exposure can vary across patients, injection sites, disease states, and delivery workflows. For some therapies, this may affect exposure predictability and treatment consistency.
- Variable absorption may shift exposure below, within, or above a target range
- Below-target exposure may reduce the likelihood of adequate response
- Above-target exposure may increase the risk of tolerability or safety concerns
- More predictable exposure may support product, delivery-system, and lifecycle decisions
Illustrative exposure schematic. Evaluation requirements depend on the molecule, product presentation, use case, and partner evidence objectives.
Platform Architecture
Preserve the Molecule, Address the Administration Site
RayBalance's drug-adjacent, administration-site platform is designed to support more predictable subcutaneous delivery performance while preserving a partner's drug product and development strategy. It focuses on administration-site conditions that may contribute to absorption variability.
Partner Drug Product Assets
- Molecule
- Formulation
- Excipient system
- Container closure
- Regulatory strategy
→
RayBalance Administration-Site Platform
- Non-reformulation
- Drug-adjacent
- Administration-site focused
- Partner-specific evaluation
→
Partner-Specific Evidence Path
- Feasibility assessment
- PK evaluation where appropriate
- Usability and integration planning
- Regulatory alignment
Partner Opportunities
Built for Pharmaceutical, Biosimilar, and Device Partners
RayBalance is focused on opportunities where subcutaneous absorption performance, variability, administration workflow, lifecycle strategy, or IV-to-SC transition presents a meaningful development or delivery challenge.
Lifecycle Strategy
Extend franchise value with a non-reformulation lifecycle strategy built on administration performance, not molecule change.
IV-to-SC Transition
Support practical IV-to-SC conversion and lower-burden administration strategies for high-value therapies.
Delivery-System and Device Partners
Pair administration-site enhancement with injector, pump, on-body, and connected-delivery platforms to expand combination-product capability.
Development Approach
Evidence-Driven and Partner-Specific
RayBalance is building its platform through a staged evidence program focused on administration-site biology, absorption-relevant endpoints, safety, usability, and molecule-specific pharmacokinetic evaluation where appropriate.
Detailed technical information, proprietary methods, device configuration, treatment parameters, and molecule-specific development plans are disclosed only under appropriate confidentiality protections.
1
Strategic Fit
Understand the partner's product, opportunity, and development context.
2
Feasibility Assessment
Evaluate potential alignment with the administration-performance challenge.
3
Evidence Plan
Define the right evidence strategy for the partner opportunity.
4
Molecule-Specific Evaluation
Conduct PK and other evaluation where appropriate.
5
Regulatory and Integration Alignment
Align on regulatory strategy and delivery-system integration.
Contact
Connect with RayBalance
RayBalance is interested in discussions with pharmaceutical companies, biosimilar manufacturers, medical device companies, and strategic partners evaluating subcutaneous delivery performance, lifecycle strategy, or IV-to-SC transition opportunities.
Please do not submit confidential information through this form.
Business Development Inquiries
3830 Valley Centre Drive, STE 705-224
San Diego, CA 92130
Start a Conversation
Fields marked with an asterisk are required.